Development of a unique small molecule modulator of cxcr4

PLoS ONE

Volumn 7, Issue 4, 2012, Pages

  Liang, Zhongxing ^a   Zhan, Weiqiang ^b   Zhu, Aizhi ^a   Yoon, Younghyoun ^a   Lin, Songbai ^a   Sasaki, Maiko ^a   Klapproth, Jan Michael A ^a   Yang, Hua ^a   Grossniklaus, Hans E ^a   Xu, Jianguo ^a   Rojas, Mauricio ^a   Voll, Ronald J ^a   Goodman, Mark M ^a,b   Arrendale, Richard F ^b   Liu, Jin ^b   Yun, C Chris ^a   Snyder, James P ^b   Liotta, Dennis C ^b   Shim, Hyunsuk ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; DOCUSATE SODIUM; MSX 122; N,N' [1,4 PHENYLENEBIS(METHYLENE)]DIPYRIMIDIN 2 AMINE; STROMAL CELL DERIVED FACTOR 1; UNCLASSIFIED DRUG; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; CXCR4 PROTEIN, HUMAN; N,N' (1,4 PHENYLENEBIS(METHYLENE))DIPYRIMIDIN 2 AMINE; N,N'-(1,4-PHENYLENEBIS(METHYLENE))DIPYRIMIDIN-2-AMINE; PYRIMIDINE DERIVATIVE;

AMINATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BINDING AFFINITY; BREAST CANCER; COLITIS; CONTROLLED STUDY; CROHN DISEASE; DRUG EFFICACY; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SYNTHESIS; DRUG TARGETING; HEAD AND NECK CANCER; IMMUNOMODULATION; LIVER METASTASIS; LUNG FIBROSIS; LUNG METASTASIS; METASTASIS INHIBITION; MICROMETASTASIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PAW EDEMA; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; UVEA MELANOMA; ANIMAL; BREAST TUMOR; C57BL MOUSE; CHEMICAL STRUCTURE; CHEMICALLY INDUCED DISORDER; COMPUTER SIMULATION; DRUG ANTAGONISM; DRUG DESIGN; DRUG EFFECT; DRUG SCREENING; EDEMA; FEMALE; FIBROSIS; HEAD AND NECK TUMOR; HUMAN; LIVER TUMOR; LUNG; LUNG TUMOR; MALE; MELANOMA; METABOLISM; METASTASIS; NUDE MOUSE; PATHOLOGY; PROTEIN BINDING; TUMOR CELL LINE; UVEA TUMOR;

ANIMALIA; MURINAE;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; COLITIS; COMPUTER SIMULATION; DRUG DESIGN; EDEMA; FEMALE; FIBROSIS; HEAD AND NECK NEOPLASMS; HUMANS; LIVER NEOPLASMS; LUNG; LUNG NEOPLASMS; MALE; MELANOMA; MICE; MICE, INBRED C57BL; MICE, NUDE; MODELS, MOLECULAR; PROTEIN BINDING; PYRIMIDINES; RECEPTORS, CXCR4; UVEAL NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84859227686     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0034038     Document Type: Article

References (55)

1. Davis CB, Dikic I, Unutmaz D, Hill CM, Arthos J, et al. (1997) Signal transduction due to HIV-1 envelope interactions with chemokine receptors CXCR4 or CCR5. J Exp Med 186: 1793-1798.
2. Feng Y, Broder CC, Kennedy PE, Berger EA, (1996) HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 272: 872-877.
3. Sanchez X, Cousins-Hodges B, Aguilar T, Gosselink P, Lu Z, et al. (1997) Activation of HIV-1 coreceptor (CXCR4) mediates myelosuppression. J Biol Chem 272: 27529-27531.
4. Zaitseva M, Blauvelt A, Lee S, Lapham CK, Klaus-Kovtun V, et al. (1997) Expression and function of CCR5 and CXCR4 on human Langerhans cells and macrophages: implications for HIV primary infection. Nat Med 3: 1369-1375.
5. Calandra G, Bridger G, Fricker S, (2010) CXCR4 in clinical hematology. Curr Top Microbiol Immunol 341: 173-191.
6. Zlotnik A, (2006) Involvement of chemokine receptors in organ-specific metastasis. Contrib Microbiol 13: 191-199.
7. Liotta LA, Kohn EC, (2001) The microenvironment of the tumour-host interface. Nature 411: 375-379.
8. Porta C, Riboldi E, Sica A, (2010) Mechanisms linking pathogens-associated inflammation and cancer. Cancer Lett.
9. Lazennec G, Richmond A, (2010) Chemokines and chemokine receptors: new insights into cancer-related inflammation. Trends Mol Med 16: 133-144.
10. Kucia M, Reca R, Miekus K, Wanzeck J, Wojakowski W, et al. (2005) Trafficking of normal stem cells and metastasis of cancer stem cells involve similar mechanisms: pivotal role of the SDF-1-CXCR4 axis. Stem Cells 23: 879-894.
11. Furusato B, Mohamed A, Uhlen M, Rhim JS, (2010) CXCR4 and cancer. Pathol Int 60: 497-505.
12. Weinberg RA, (2007) The Biology of Cancer: Garland Science.
13. Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, et al. (2003) A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3: 537-549.
14. Muller A, Homey B, Soto H, Ge N, Catron D, et al. (2001) Involvement of chemokine receptors in breast cancer metastasis. Nature 410: 50-56.
15. Balkwill F, (2004) The significance of cancer cell expression of the chemokine receptor CXCR4. Semin Cancer Biol 14: 171-179.
16. Shim H, Oishi S, Fujii N, (2009) Chemokine receptor CXCR4 as a therapeutic target for neuroectodermal tumors. Semin Cancer Biol 19: 123-134.
17. De Clercq E, (2003) The bicyclam AMD3100 story. Nat Rev Drug Discov 2: 581-587.
18. Strieter RM, Keeley EC, Hughes MA, Burdick MD, Mehrad B, (2009) The role of circulating mesenchymal progenitor cells (fibrocytes) in the pathogenesis of pulmonary fibrosis. J Leukoc Biol 86: 1111-1118.
19. Schiffer D, Annovazzi L, Caldera V, Mellai M, (2012) On the origin and growth of gliomas. Anticancer Res 30: 1977-1998.
20. Liang Z, Wu T, Lou H, Yu X, Taichman RS, et al. (2004) Inhibition of breast cancer metastasis by selective synthetic polypeptide against CXCR4. Cancer Res 64: 4302-4308.
21. Yoon Y, Liang Z, Zhang X, Choe M, Cho HT, et al. (2007) CXCR4 antagonist blocks both growth of primary tumor and metastasis of head and neck cancer in xenograft mouse models. Cancer Res 67: 7518-7524.
22. Xu J, Mora A, Shim H, Stecenko A, Brigham KL, et al. (2007) Role of the SDF-1/CXCR4 Axis in the Pathogenesis of Lung Injury and Fibrosis. Am J Respir Cell Mol Biol.
23. Zhan W, Liang Z, Zhu A, Kurtkaya S, Shim H, et al. (2007) Discovery of small molecule CXCR4 antagonists. J Med Chem 50: 5655-5664.
24. Abdel-Magid AF, Carson KG, Harris BD, Maryanoff CA, Shah RD, (1996) Reductive Amination of Aldehydes and Ketones with Sodium Triacetoxyborohydride. Studies on Direct and Indirect Reductive Amination Procedures(1). J Org Chem 61: 3849-3862.
25. Thelen M, Thelen S, (2008) CXCR7, CXCR4 and CXCL12: an eccentric trio? J Neuroimmunol 198: 9-13.
26. Wang J, Shiozawa Y, Wang J, Wang Y, Jung Y, et al. (2008) The role of CXCR7/RDC1 as a chemokine receptor for CXCL12/SDF-1 in prostate cancer. J Biol Chem 283: 4283-4294.
27. Gupta SK, Pillarisetti K, Thomas RA, Aiyar N, (2001) Pharmacological evidence for complex and multiple site interaction of CXCR4 with SDF-1alpha: implications for development of selective CXCR4 antagonists. Immunol Lett 78: 29-34.
28. Fricker SP, Anastassov V, Cox J, Darkes MC, Grujic O, et al. (2006) Characterization of the molecular pharmacology of AMD3100: a specific antagonist of the G-protein coupled chemokine receptor, CXCR4. Biochem Pharmacol 72: 588-596.
29. Kalatskaya I, Berchiche YA, Gravel S, Limberg BJ, Rosenbaum JS, et al. (2009) AMD3100 is a CXCR7 ligand with allosteric agonist properties. Mol Pharmacol 75: 1240-1247.
30. Kofuku Y, Yoshiura C, Ueda T, Terasawa H, Hirai T, et al. (2009) Structural basis of the interaction between chemokine stromal cell-derived factor-1/CXCL12 and its G-protein-coupled receptor CXCR4. J Biol Chem 284: 35240-35250.
31. Crump MP, Gong JH, Loetscher P, Rajarathnam K, Amara A, et al. (1997) Solution structure and basis for functional activity of stromal cell-derived factor-1; dissociation of CXCR4 activation from binding and inhibition of HIV-1. EMBO J 16: 6996-7007.
32. Wang J, Zhang X, Thomas SM, Grandis JR, Wells A, et al. (2005) Chemokine receptor 7 activates phosphoinositide-3 kinase-mediated invasive and prosurvival pathways in head and neck cancer cells independent of EGFR. Oncogene 24: 5897-5904.
33. Wu B, Chien EY, Mol CD, Fenalti G, Liu W, et al. (2010) Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science 330: 1066-1071.
34. Friesner RA, Banks JL, Murphy RB, Halgren TA, Klicic JJ, et al. (2004) Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem 47: 1739-1749.
35. Halgren TA, Murphy RB, Friesner RA, Beard HS, Frye LL, et al. (2004) Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. J Med Chem 47: 1750-1759.
36. Sherman W, Day T, Jacobson MP, Friesner RA, Farid R, (2006) Novel procedure for modeling ligand/receptor induced fit effects. J Med Chem 49: 534-553.
37. Graves AP, Shivakumar DM, Boyce SE, Jacobson MP, Case DA, et al. (2008) Rescoring docking hit lists for model cavity sites: predictions and experimental testing. J Mol Biol 377: 914-934.
38. Guimaraes CR, Cardozo M, (2008) MM-GB/SA rescoring of docking poses in structure-based lead optimization. J Chem Inf Model 48: 958-970.
39. Xia XM, Wang FY, Xu WA, Wang ZK, Liu J, et al. (2010) CXCR4 antagonist AMD3100 attenuates colonic damage in mice with experimental colitis. World J Gastroenterol 16: 2873-2880.
40. Mikami S, Nakase H, Yamamoto S, Takeda Y, Yoshino T, et al. (2008) Blockade of CXCL12/CXCR4 axis ameliorates murine experimental colitis. J Pharmacol Exp Ther 327: 383-392.
41. Castaneda FE, Walia B, Vijay-Kumar M, Patel NR, Roser S, et al. (2005) Targeted Deletion of Metalloproteinase 9 Attenuates Experimental Colitis in Mice: Central Role of Epithelial-Derived MMP. Gastroenterology 129: 1991-2008.
42. Andres PG, Beck PL, Mizoguchi E, Mizoguchi A, Bhan AK, et al. (2000) Mice with a Selective Deletion of the CC Chemokine Receptors 5 or 2 Are Protected from Dextran Sodium Sulfate-Mediated Colitis: Lack of CC Chemokine Receptor 5 Expression Results in a NK1.1+ Lymphocyte-Associated Th2-Type Immune Response in the Intestine. J Immunol 164: 6303-6312.
43. Sasaki T, Sasaki J, Sakai T, Takasuga S, Suzuki A, (2007) The physiology of phosphoinositides. Biol Pharm Bull 30: 1599-1604.
44. Boudeau J, Glasser A-L, Masseret E, Joly B, Darfeuille-Michaud A, (1999) Invasive Ability of an Escherichia coli Strain Isolated from the Ileal Mucosa of a Patient with Crohn's Disease. Infect Immun 67: 4499-4509.
45. Zhu A, Zhan W, Liang Z, Yoon Y, Yang H, et al. (2010) Dipyrimidine Amines: A novel class of chemokine receptor type 4 antagonists with high specifity. J Med Chem 53: 8556-8568.
46. Yang H, Fang G, Huang X, Yu J, Hsieh CL, et al. (2008) In-vivo xenograft murine human uveal melanoma model develops hepatic micrometastases. Melanoma Res 18: 95-103.
47. Yang H, Grossniklaus HE, (2006) Combined immunologic and anti-angiogenic therapy reduces hepatic micrometastases in a murine ocular melanoma model. Curr Eye Res 31: 557-562.
48. Dorsam RT, Gutkind JS, (2007) G-protein-coupled receptors and cancer. Nat Rev Cancer 7: 79-94.
49. Gao C, Li Y, (2007) SDF-1 plays a key role in the repairing and remodeling process on rat allo-orthotopic abdominal aorta grafts. Transplant Proc 39: 268-272.
50. Imitola J, Raddassi K, Park KI, Mueller FJ, Nieto M, et al. (2004) Directed migration of neural stem cells to sites of CNS injury by the stromal cell-derived factor 1alpha/CXC chemokine receptor 4 pathway. Proc Natl Acad Sci U S A 101: 18117-18122.
51. Kajiyama H, Shibata K, Ino K, Nawa A, Mizutani S, et al. (2007) Possible involvement of SDF-1alpha/CXCR4-DPPIV axis in TGF-beta1-induced enhancement of migratory potential in human peritoneal mesothelial cells. Cell Tissue Res 330: 221-229.
52. Moyer RA, Wendt MK, Johanesen PA, Turner JR, Dwinell MB, (2007) Rho activation regulates CXCL12 chemokine stimulated actin rearrangement and restitution in model intestinal epithelia. Lab Invest 87: 807-817.
53. Liang Z, Brooks J, Willard M, Liang K, Yoon Y, et al. (2007) CXCR4/CXCL12 axis promotes VEGF-mediated tumor angiogenesis through Akt signaling pathway. Biochem Biophys Res Commun 359: 716-722.
54. Lin S, Yeruva S, He P, Singh AK, Zhang H, et al. (2010) Lysophosphatidic acid stimulates the intestinal brush border Na(+)/H(+) exchanger 3 and fluid absorption via LPA(5) and NHERF2. Gastroenterology 138: 649-658.
55. Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG, (2010) Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol 8: e1000412.